Please login to the form below

Not currently logged in
Email:
Password:

PharmaLex strikes up AI collaboration with Volv

The duo will develop pharmacovigilance products and services

PharmaLexDevelopment consulting and affairs group PharmaLex has teamed up with privately held Volv Global to bolster its pharmacovigilance business.

The project will see the duo use artificial intelligence (AI) technology, such as Volv’s predictive technologies, unassisted machine learning, paradigms and web-scale technologies, to develop products and services for PharmaLex’s clients.

Dr Thomas Dobmeyer, chief executive officer of PharmaLex, said: “The increasing volume of relevant literature in the medico-scientific domain is a challenge.

“Embedded artificial intelligence and cognitive computing technology allows for increased efficiency, especially in the area of drug adverse even monitoring.

Initially focusing on pharmacovigilance services, the project will centre in on supporting and monitoring adverse events that recorded on web forums and social media channels, regulatory intelligence platforms, patient identification for rare diseases and related services.

Christopher Rudolf, founder and chief executive officer of Volv Global, said: “We are delighted to be working with PharmaLex on the development of their pharmacovigilance (PV) solutions.

“Our innovative technology has an open design and intuitive interface, ensuring it can easily integrate into existing PV platforms.”

Article by
Gemma Jones

6th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics